

Application of Artificial Intelligent in Healthcare

Ethan Garnier^{1*}, Matthew Tidd² and Minh Nguyen²

¹Electrical and Computer Engineering Department, UNB

²Mechanical Engineering Department, UNB

{ethan.garnier78, matthew.tidd, mnguyen6}@unb.ca

Abstract

This short example shows a contrived example on how to format the authors' information for *IJCAI-19 Proceedings* using \LaTeX .

1 Introduction

This short example shows a contrived example on how to format the authors' information for *IJCAI-19 Proceedings*.

2 History of AI in Healthcare

2.1 Recent Developments in Healthcare AI

Ever since the age of big data, there has been a surge in AI developments. This acceleration originates from several factors, including the wealth of data collected by big tech, the decreased cost of computational power, developments of more efficient machine learning techniques, and the availability of open-source machine learning packages. The healthcare and medical fields are no exclusion from this wave of AI developments. In fact, AI and ML application is an active field of research, receiving attention from researchers, medical stakeholders, and policy makers. The immersion of the technology in the medical field is evident in the growth of FDA-approved AI/ML-enabled medical devices in Figure 1 [1]




Figure 1: Number of FDA-approved AI/ML-enabled medical devices since 2010

Radiology

In radiology, machine learning is a powerful tool that can help physicians with CT scan and MRI scan to diagnose diseases and extract latent insights from the scans. Some example work include

- Classification of triple negative breast cancer using ultrasound images [2]
- Detection of pulmonary lung nodules from CT scans by convolutional neural network [3]
- Pneumonia detection from chest X-rays using modern deep learning [4]
- Detection of breast mass from mammography scans using convolutional neural networks [5]

Dermatology

In dermatology diagnosis, visual inspection remains the prominent method for determining the severity of a skin abnormalities or lesions. Machine learning emerges as an effective automation method as they learn the latent features that differentiate between benign and malignant lesions in skin melanoma. As early as 1994, the research in [6] applied neural network to automate the classification of malignant melanoma from melanoma-like benign tumors. The model was given the discriminant characteristics such as tumor shape and relative color, manually extracted from digital images of skin cancer. In [7], a convolutional neural network was trained on 100,000 clinical images of skin cancer and achieved an accuracy similar to that of a dermatologist. Once these models have been trained extensively on computationally efficient hardware, they can be packaged and deployed on mobile devices to make inferences on skin lesions. This can further increase the accessibility of machine learning functionalities to the wider population.

Hematology

In the case of hematological diseases, early prediction can help prevent progression and complication of blood disorders such as leukemia and lymphoma. Traditionally, practitioners diagnose hematological conditions by cytomorphologic phenotypic assessment of peripheral blood (PB) and bone marrow (BM) samples. Newer techniques for disease diagnosis includes flow cytometry and molecular genetic analyses. However, diagnostic ambiguity often occurs in such manual

*Contact Author

process depending on the operator experience and capabilities. The reproducibility of clinical results suffer from inter- and intravariations amongst skilled hematologists and pathologists [8; 9]. Therefore, there needs to be an automated process for reduced reliance on expert knowledge and increased consistency in data interpretation. Given its predictive power, machine learning implementation in disease diagnosis from blood samples is an active research topic.

In 2014, early developments of automated ML systems for cytomorphologic assessment had limited capabilities, performing tasks such as blood cell counting or classification of lymphoid cell types [10; 11; 12]. In [13], two ML models were developed to predict hematologic disease. One of them was trained on all available blood test parameters and the other trained on a reduced set of parameters usually obtained from patient admittance. When this input is paired with the knowledge of the five most likely diseases, the models achieve predictive performance on par with haematology specialists. In a research by *Wu et al.* [9], the researchers developed a BMSNet with the YOLO-v3 CNN architecture to assist in BM smear interpretation. The model performance was reported as comparable to that of expert hematologists and pathologists in various tests, except for the classification of myelodysplastic cases. *Matek et al.* [14] automated cytomorphologic examination of BM smears by training two CNN-based classifiers. The first model has the ResNeXt-50 architecture, previously used in [15] for recognition of acute myeloid leukemia blast cells from PB smears due to its low number of hyperparameters. The second model was a sequential CNN models with a simpler architecture for baseline performance comparison. The research in [16] employed a two-stage CNN architecture to classifies four types of white blood cells (leukocytes). The first layer of CNN leveraged a Faster R-CNN network to delineate the regions of interest and differentiate mononuclear cells from polymorphonuclear cells. The second layer consists of two parallel CNN with the MobileNet architectures and transfer learning to further categorize the subclasses of leukocytes. The lightweight architecture and parallelization in the second layer allows for faster inferencing time.

Flow cytometry or multiparameter flow cytometry (MFC) is a modern techniques for routine blood analysis and an enabling factor for AI integration in hematology. Modern MPC can analyze thousands of cells a second to generate a large dataset of high dimensional data [8]. Although this appears challenging for human interpretation and emphasizes the reliance on expert knowledge, a machine learning algorithm can be trained to interpret the latent representation and correlation in the flow cytometry data. The researchers in [17], leveraged machine learning by first converting MPC data into multicolor 2D images using a self-organizing map before feeding this data representation through a CNN architecture for classification. The developed model was capable of categorizing healthy cells from diseased ones, as well as the seven subclasses of mature B-cell neoplasm.

Ophthalmology

In the field of ophthalmology, a funduscopy is a non invasive procedure for investigating the patient's fundus, or the back

of their eyes, to diagnose vision conditions and risk factors leading to vision loss. These detected factors can be used to predict the onset of diseases such as diabetic retinopathy, glaucoma, retina neoplasms, and macular degeneration [18]

Diabetic retinopathy (DR) is a condition where high blood sugar level causes damaged vessel in the retina. This condition is one of the common causes of vision loss and impairment amongst American living with diabetes and working age adults [19; 20]. In 2018, the FDA approved of IDx-DR, the first AI-enabled system for detecting DR. The research in [21] and [20] leveraged a multilayer CNN to train independent detectors for the anatomy and the characteristics of DR, including microaneurysms, hemorrhages, and lipoprotein exudates. The results of these detectors are combined to return the levels of the diseases. The study in [22] implemented an Inception-v4 CNN architecture, to detect the severity grade of DR and provide a heatmap of regions of interest.

Researchers have also integrated AI into the early diagnosis of **age-related macular degeneration (AMD)**, a chronic and irreversible condition and one of the most common cause of central vision loss. One characteristics that signals the onset of AMD is the appearance of hard or soft drusen on optical coherence tomography (OCT) images or color funduscopy images. ML can automate the drusen detection to diagnose early signs of AMD, such as in *Burlina et. al* [23] where they employed Deep CNN on color fundus images. The network employs transfer learning on the AlexNet structure, which includes dropout layers, ReLU activation, and normalization. The weights was trained using stochastic gradient descent and Nesterov momentum, and a learning rate of 0.001 for 50 epochs. This model was compared to a pretrained Overfeat DCNN (New York University) with a linear SVM for classification. The results showed comparable performance to expert human graders, with accuracy ranging from 88.4% and 91.6% and an ROC-AUC score between 0.94 and 0.96. In the research done by *Schlegel et al.* [24], the authors adopted an autoencoder architecture and CNN for learning a simplified representation of the raw images (Figure 2 shows the architecture of this network). The encoder portion of this networks generates an optimized abstract representation of the data embedding, which is then used to re-generate a corresponding image with class labels.

Glaucoma is another medical condition resulting in damaged optic nerve. The condition happens when there is a blockage preventing the drainage of the aqueous humor fluid and leading to pressure build-up in the eye. In *Shibata et al.* [25], the authors developed a deep residual network (ResNet) for glaucoma detection from 2D fundus photography. The network is based on the CNN architecture with residual connections to prevent the gradient vanishing and gradient divergence problem, thus allowing for more effective training of deeper networks. In a recent study by *Thompson et al.* [26], the authors implemented a deep learning solution for glaucoma detection using B-scan from OCT images. This research employed a residual deep convolutional neural network (ResNet34) and transfer learning to leverage the previously trained feature extraction layers on the ImageNet dataset.




Figure 2: The proposed network with an autoencoder architecture using CNN in the encoder portion to form a simplified representation of the input features

Oncology

The integration of AI and ML systems in cancer treatment is an active branch of research. Some potential use cases of AI in this field of research are radiotherapy dosage optimization and image segmentation for tissue abnormality detection. AI algorithms have shown promising improvements compared to manual planning in these fields [27]. In radiation treatment, the prescribed dose is determined by specialist prior to initial treatment. This knowledge base planning approach depends on dose histograms and historical patient plans. However, the variations in tumour biology poses challenges to this process as the dosage can significantly vary. Further complication may arise depending on the location of the tumour and surrounding organs, thus preventing the desired dosage delivery [28]. In this sense, AI methods can personalize the treatment plan and the optimal prescription achievable depending on the contour of the tumour and organs.

In *Nguyen et al.* [29], the authors leveraged the modified U-net CNN network (Figure 3) to achieve contour-to-dose mapping. The U-Net architecture was first introduced in [30] for image segmentation task. In a U-Net, the compressed representation of image data that was learned in the *contracting path* undergoes up sampling and up-convolutions in the *expansive path*. The features in the expansive path are combined with high-resolution feature from the contracting path to create the segmented representation.

3 Challenges

3.1 Trust

3.2 Accountability

3.3 Data privacy and protection

AI technologies depend on a vast amount of patient data and record to make accurate predictions when subjected to unseen data. However, in the event of a database violation or data breach, confidential patient information can be exploited for malicious intentions (identity theft, social stigma, discrimination,...). This can put a mental burden on the patient susceptible to the violation and other relevant stakeholders. Therefore, adequate law and guidelines are crucial to regulate the application of AI in medical and prevent misuse of data

The data gathering and handling of health data in the US is controversial, raising legal and ethical privacy questions [31]. Although the data can originate from various sources, such as healthcare providers, insurance claim, and wearable devices, US privacy law operates in different extents depending on the data source. This law also depends on the custodian of the data. Under the Health Insurance Portability and Accountability Act (HIPAA), the federal Privacy Rule only governs data handling between the conventional entities, such as healthcare providers, health insurance providers, patients, and intermediaries. However, [31] pointed out existing gap in HIPAA regulation. Although, HIPAA protect patient privacy from health data breach via a deidentifying process, patient data can be reidentified through data triangulation from other datasets.

Furthermore, a more fundamental problem is the amount of health related data not regulated under HIPAA [31]. Originally enacted to regulate data privacy in health records and between covered entities, HIPAA does not account for health data generate outside the confinement of these covered entities. In the big data world, tech companies are displacing covered entities in the collection of health information and personal data from online searches, application logs, and smart wearable devices.

4 Case Study: From Turing Award to Nobel Prizes

Artificial intelligence (AI) and machine learning (ML), two transformative forces within computer science, are undeniably making rippling effects into other traditional technological fields. The prestigious 2018 Turing Award honored Geoffrey Hinton, a trailblazer in artificial neural network, for his earlier pioneering work that paved the way for recent AI developments. This landmark achievement highlighted the fundamental role of AI in advancing computer science and unravelling the complexities of natural systems—a contribution that recently earned Hinton the 2024 Nobel Prize in Physics. Shortly after Hinton’s recognition, Demis Hassabis and John Jumper, two Google DeepMind executives, received the Nobel Prize in Chemistry for their pioneering contributions to decoding microscopic protein structures in the AlphaFold project. Using advanced AI-driven approaches, they created




Figure 3: Modified U-Net architecture for personalized prostate cancer dosage prescription based on patient anatomy

solutions capable of predicting protein folding—a pivotal biological challenge as a protein’s structure directly determines its function within cells and organisms. This AI breakthrough has fundamentally transformed biochemistry, enabling rapid drug discovery, personalized medicine, and a deeper understanding of cellular mechanisms.

4.1 History of AlphaFold Development


The first version of AlphaFold [32] made its debut at the 13th Critical Assessment of protein Structure Prediction (CASP13), a global competition that evaluates the latest methods for predicting protein structure. This task is known for its complexity due to the vast number of potential ways protein chains can fold. AlphaFold introduced an innovative approach that combined deep neural networks with reinforcement learning to predict the 3D structure of proteins with higher accuracy than previous methods. The algorithm uses a multiple sequence alignment technique (MSA) to process protein sequence data and related evolutionary data to understand amino acid relationship. This techniques provides information about conserved amino acids accross similar proteins and offers clues of possible protein folding structure. AlphaFold’s CNN architecture analyzed these features, learning patterns in amino acid interactions and generating predictions on the likely contacts between amino acid pairs. After initial training, AlphaFold employed reinforcement learning techniques to refine predictions iteratively, adjusting the protein’s structure until it reached a stable conformation. By rewarding predictions that brought the structure closer to plausible physical conformations, AlphaFold improved the reliability of its results over successive iterations.

AlphaFold 2 was a major leap forward and was presented

at CASP14 in 2020. This version used a new architecture that relied heavily on attention mechanisms, allowing it to focus on relationships between amino acids and to understand how they influence a protein’s folding process [33]. The approach resembled “transformer” models commonly used in natural language processing, which helped AlphaFold 2 capture intricate dependencies within protein Figure 4. The two main attention pathways - pairwise interaction representation and evoformer block - were introduced to help the model analyzed these long-range dependencies. The first attention architecture provides understanding on amino acids interaction within the folded structure, while the second pathway is a series of transformer layers that compbine both sequence information and the pairwise interaction data to build a cohesive representation of the protein’s 3D structure. The algorithm further refines its prediction iteratively given the physical constraints and previous predictions and produce progressively more accurate predictions. The AlphaFold 2 algorithm achieve to an average accuracy comparable to experimental methods for many proteins.

As many biological functions are carried out by protein complexes, DeepMind introduced AlphaFold-Multimer v2.3, an extension designed to predict the structure of protein complexes (multimers) rather than individual proteins. This version builds on AlphaFold 2’s framework, adapting it to better handle interactions between multiple protein chains, which are crucial in many biological processes.

Compared to AlphaFold 2 and AlphaFold Multimer, which can model protein monomers and protein complexes, AlphaFold 3 was capable of modeling the interaction amongst a wider range of biomolecules such as ligands, nucleic acids, and modified residues [34]. AlphaFold 3 introduced a 2 new






Figure 5: AlphaFold 3 architectures

- melanoma from color images,” *IEEE transactions on bio-medical engineering*, vol. 41, no. 9, pp. 837–845, Sep. 1994.
- [7] A. Esteva, B. Kuprel, R. A. Novoa, J. Ko, S. M. Swetter, H. M. Blau, and S. Thrun, “Dermatologist-level classification of skin cancer with deep neural networks,” *Nature*, vol. 542, no. 7639, pp. 115–118, Feb. 2017, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/nature21056>
 - [8] W. Walter, C. Pohlkamp, M. Meggendorfer, N. Nadarajah, W. Kern, C. Haferlach, and T. Haferlach, “Artificial intelligence in hematological diagnostics: Game changer or gadget?” *Blood Reviews*, vol. 58, p. 101019, Mar. 2023. [Online]. Available: <https://linkinghub.elsevier.com/retrieve/pii/S0268960X22000935>
 - [9] Y.-Y. Wu, T.-C. Huang, R.-H. Ye, W.-H. Fang, S.-W. Lai, P.-Y. Chang, W.-N. Liu, T.-Y. Kuo, C.-H. Lee, W.-C. Tsai, and C. Lin, “A Hematologist-Level Deep Learning Algorithm (BMSNet) for Assessing the Morphologies of Single Nuclear Balls in Bone Marrow Smears: Algorithm Development,” *JMIR Medical Informatics*, vol. 8, no. 4, p. e15963, Apr. 2020, company: JMIR Medical Informatics Distributor: JMIR Medical Informatics Institution: JMIR Medical Informatics Label: JMIR Medical Informatics Publisher: JMIR Publications Inc., Toronto, Canada. [Online]. Available: <https://medinform.jmir.org/2020/4/e15963>
 - [10] Y. M. Alomari, S. N. H. Sheikh Abdullah, R. Zaharatul Azma, and K. Omar, “Automatic Detection and Quantification of WBCs and RBCs Using Iterative Structured Circle Detection Algorithm,” *Computational and Mathematical Methods in Medicine*, vol. 2014, no. 1, p. 979302, 2014, eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1155/2014/979302>, [Online]. Available: <https://onlinelibrary.wiley.com/doi/abs/10.1155/2014/979302>
 - [11] S. Alf  rez, A. Merino, L. E. Mujica, M. Ruiz, L. Bigorra, and J. Rodellar, “Automatic classification of atypical lymphoid B cells using digital blood image processing,” *International Journal of Laboratory Hematology*, vol. 36, no. 4, pp. 472–480, 2014, eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.12175>. [Online]. Available: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.12175>
 - [12] S. Alf  rez, A. Merino, L. Bigorra, L. Mujica, M. Ruiz, and J. Rodellar, “Automatic recognition of atypical lymphoid cells from peripheral blood by digital image analysis,” *American Journal of Clinical Pathology*, vol. 143, no. 2, pp. 168–176, 2015.
 - [13] G. Gun  ar, M. Kukar, M. Notar, M. Brvar, P.   ernel  , M. Notar, and M. Notar, “An application of machine learning to haematological diagnosis,” *Scientific Reports*, vol. 8, no. 1, p. 411, Jan. 2018, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41598-017-18564-8>
 - [14] C. Matek, S. Krappe, C. M  nzenmayer, T. Haferlach, and C. Marr, “Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set,” *Blood*, vol. 138, no. 20, pp. 1917–1927, Nov. 2021. [Online]. Available: <https://ashpublications.org/blood/article/138/20/1917/477932/Highly-accurate-differentiation-of-bone-marrow>
 - [15] C. Matek, S. Schwarz, K. Spiekermann, and C. Marr, “Human-level recognition of blast cells in acute myeloid leukemia with convolutional neural networks,” Feb. 2019. [Online]. Available: <http://biorxiv.org/lookup/doi/10.1101/564039>
 - [16] C. Cheuque, M. Querales, R. Le  n, R. Salas, and R. Torres, “An Efficient Multi-Level Convolutional Neural Network Approach for White Blood Cells Classification,” *Diagnostics*, vol. 12, no. 2, p. 248, Feb. 2022, number: 2 Publisher: Multidisciplinary Digital Publishing Institute. [Online]. Available: <https://www.mdpi.com/2075-4418/12/2/248>
 - [17] M. Zhao, N. Mallesh, A. H  llein, R. Schabath, C. Haferlach, T. Haferlach, F. Elsner, H. L  ling, P. Krawitz, and W. Kern, “Hematologist-Level Classification of Mature B-Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data,” *Cytometry Part A*, vol. 97, no. 10, pp. 1073–1080, 2020, eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.a.24159>. [Online]. Available: <https://onlinelibrary.wiley.com/doi/abs/10.1002/cyto.a.24159>

- [18] P. Kumar, S. Chauhan, and L. K. Awasthi, "Artificial Intelligence in Healthcare: Review, Ethics, Trust Challenges & Future Research Directions," *Engineering Applications of Artificial Intelligence*, vol. 120, p. 105894, Apr. 2023. [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S0952197623000787>
- [19] O. o. t. Commissioner, "FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems," Mar. 2020, publisher: FDA. [Online]. Available: <https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-artificial-intelligence-based-device-detect-certain-diabetes-related-eye>
- [20] M. D. Abramoff, P. T. Lavin, M. Birch, N. Shah, and J. C. Folk, "Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices," *npj Digital Medicine*, vol. 1, no. 1, pp. 1–8, Aug. 2018, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41746-018-0040-6>
- [21] M. D. Abramoff, Y. Lou, A. Erginay, W. Clarida, R. Amelon, J. C. Folk, and M. Niemeijer, "Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning," *Investigative Ophthalmology & Visual Science*, vol. 57, no. 13, pp. 5200–5206, Oct. 2016. [Online]. Available: <https://doi.org/10.1167/iops.16-19964>
- [22] R. Sayres, A. Taly, E. Rahimy, K. Blumer, D. Coz, N. Hammel, J. Krause, A. Narayanaswamy, Z. Rastegar, D. Wu, S. Xu, S. Barb, A. Joseph, M. Shumski, J. Smith, A. B. Sood, G. S. Corrado, L. Peng, and D. R. Webster, "Using a Deep Learning Algorithm and Integrated Gradients Explanation to Assist Grading for Diabetic Retinopathy," *Ophthalmology*, vol. 126, no. 4, pp. 552–564, Apr. 2019. [Online]. Available: <https://linkinghub.elsevier.com/retrieve/pii/S0161642018315756>
- [23] P. M. Burlina, N. Joshi, M. Pekala, K. D. Pacheco, D. E. Freund, and N. M. Bressler, "Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks," *JAMA Ophthalmology*, vol. 135, no. 11, p. 1170, Nov. 2017. [Online]. Available: <http://archophth.jamanetwork.com/article.aspx?doi=10.1001/jamaophthalmol.2017.3782>
- [24] T. Schlegl, S. M. Waldstein, H. Bogunovic, F. Endstraßer, A. Sadeghipour, A.-M. Philip, D. Podkowinski, B. S. Gerendas, G. Langs, and U. Schmidt-Erfurth, "Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning," *Ophthalmology*, vol. 125, no. 4, pp. 549–558, Apr. 2018. [Online]. Available: <https://linkinghub.elsevier.com/retrieve/pii/S0161642017314240>
- [25] N. Shibata, M. Tanito, K. Mitsunashi, Y. Fujino, M. Matsuura, H. Murata, and R. Asaoka, "Development of a deep residual learning algorithm to screen for glaucoma from fundus photography," *Scientific Reports*, vol. 8, no. 1, p. 14665, Oct. 2018, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41598-018-33013-w>
- [26] A. C. Thompson, A. A. Jammal, S. I. Berchuck, E. B. Mariottoni, and F. A. Medeiros, "Assessment of a Segmentation-Free Deep Learning Algorithm for Diagnosing Glaucoma From Optical Coherence Tomography Scans," *JAMA Ophthalmology*, vol. 138, no. 4, p. 333, Feb. 2020. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7042899/>
- [27] R. F. Thompson, G. Valdes, C. D. Fuller, C. M. Carpenter, O. Morin, S. Aneja, W. D. Lindsay, H. J. W. L. Aerts, B. Agrimson, C. Deville, S. A. Rosenthal, J. B. Yu, and C. R. Thomas, "Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation?" *Radiotherapy and Oncology*, vol. 129, no. 3, pp. 421–426, Dec. 2018. [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S0167814018302895>
- [28] E. Huynh, A. Hosny, C. Guthrie, D. S. Bitterman, S. F. Petit, D. A. Haas-Kogan, B. Kann, H. J. W. L. Aerts, and R. H. Mak, "Artificial intelligence in radiation oncology," *Nature Reviews Clinical Oncology*, vol. 17, no. 12, pp. 771–781, Dec. 2020, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41571-020-0417-8>
- [29] D. Nguyen, T. Long, X. Jia, W. Lu, X. Gu, Z. Iqbal, and S. Jiang, "A feasibility study for predicting optimal radiation therapy dose distributions of prostate cancer patients from patient anatomy using deep learning," *Scientific Reports*, vol. 9, no. 1, p. 1076, Jan. 2019, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41598-018-37741-x>
- [30] O. Ronneberger, P. Fischer, and T. Brox, "U-Net: Convolutional Networks for Biomedical Image Segmentation," in *Medical Image Computing and Computer-Assisted Intervention – MICCAI 2015*, N. Navab, J. Hornegger, W. M. Wells, and A. F. Frangi, Eds. Cham: Springer International Publishing, 2015, pp. 234–241.
- [31] W. N. Price and I. G. Cohen, "Privacy in the age of medical big data," *Nature Medicine*, vol. 25, no. 1, pp. 37–43, Jan. 2019. [Online]. Available: <https://www.nature.com/articles/s41591-018-0272-7>
- [32] A. W. Senior, R. Evans, J. Jumper, J. Kirkpatrick, L. Sifre, T. Green, C. Qin, A. Židek, A. W. R. Nelson, A. Bridgland, H. Penedones, S. Petersen, K. Simonyan, S. Crossan, P. Kohli, D. T. Jones, D. Silver, K. Kavukcuoglu, and D. Hassabis, "Improved protein structure prediction using potentials from deep learning," *Nature*, vol. 577, no. 7792, pp. 706–710, Jan. 2020, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41586-019-1923-7>

- [33] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli, and D. Hassabis, “Highly accurate protein structure prediction with AlphaFold,” *Nature*, vol. 596, no. 7873, pp. 583–589, Aug. 2021.
- [34] J. Abramson, J. Adler, J. Dunger, R. Evans, T. Green, A. Pritzel, O. Ronneberger, L. Willmore, A. J. Ballard, J. Bambrick, S. W. Bodenstein, D. A. Evans, C.-C. Hung, M. O’Neill, D. Reiman, K. Tunyasuvunakool, Z. Wu, A. Žemgulytė, E. Arvaniti, C. Beattie, O. Bertolli, A. Bridgland, A. Cherepanov, M. Congreve, A. I. Cowen-Rivers, A. Cowie, M. Figurnov, F. B. Fuchs, H. Gladman, R. Jain, Y. A. Khan, C. M. R. Low, K. Perlin, A. Potapenko, P. Savy, S. Singh, A. Stecula, A. Thillaisundaram, C. Tong, S. Yakneen, E. D. Zhong, M. Zielinski, A. Žídek, V. Bapst, P. Kohli, M. Jaderberg, D. Hassabis, and J. M. Jumper, “Accurate structure prediction of biomolecular interactions with AlphaFold 3,” *Nature*, vol. 630, no. 8016, pp. 493–500, Jun. 2024, publisher: Nature Publishing Group. [Online]. Available: <https://www.nature.com/articles/s41586-024-07487-w>